# Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

> **NCT04680975** · PHASE2 · TERMINATED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 10 (actual)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **DRUG:** Belumosudil

## Key facts

- **NCT ID:** NCT04680975
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-03
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-12-19
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04680975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04680975, "Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04680975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*